Clinical trials: Hemophilia a
Hemophilia
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
Haemophilia is a rare and serious congenital defect of blood coagulation due to a genetic mutation on a sexual chromosome. It affects quasi-essentially the men and it is responsible for bleeding.
- Trial name
- NCT02540187
- Testing
- blood specimen
- Where
- 7 sites in France
- Volunteers
- 164 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hemophilia A
Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development
This is a clinical study to investigate how well Biostate works in treatment of male patients below the age of 12 years who have a clotting factor deficiency that is aggravated by the development of antibodies.
- Trial name
- NCT01445197
- Testing
- Biostate
- Where
- 7 sites in Austria, Germany and 3 more
- Volunteers
- 1 people
- Sponsor
- CSL Behring
HIV Infections
A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
Study A: To determine whether treatment with zidovudine (ZDV) will delay or change the disease process in hemophilic patients who have HIV infection with no symptoms.
- Trial name
- NCT00001104
- Testing
- Zidovudine
- Where
- 23 sites in United States
- Volunteers
- 538 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Hemophilia A
Emicizumab in Patients With Acquired Hemophilia A
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
- Trial name
- AHAEmi (NCT05345197)
- Testing
- emicizumab
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Washington
Hemophilia A With Inhibitor
Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction
The goal of this clinical trial is to learn how well Altuviiio (efanesoctacog alpha) works for Immune Tolerance Induction (ITI) while using Hemlibra (emicizumab) to prevent bleeds.
- Trial name
- UTILITI (NCT07158606)
- Testing
- efanesoctacog alpha, Emicizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Versiti Blood Health
Hemophilia A
ASC618 Gene Therapy in Hemophilia A Patients
Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics.
- Trial name
- NCT04676048
- Testing
- ASC618
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- ASC Therapeutics
Hemophilia C
A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery
Lately the investigators found that patients with severe factor XI deficiency and inhibitors could undergo major surgery with a single low dose of recombinant factor VIIa and tranexamic agent.
- Trial name
- rFVIIa (NCT01538160)
- Testing
- recombinant factor VIIa
- Where
- 3 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Sheba Medical Center
Haemophilia A (Moderate or Severe), Hemophilia, Classic
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
The rationale for conducting this open-label phase 4 study is to assess whether once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) improves the disease course of existing synovial hypertrophy and prevents the risk of…
- Conditions
- Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia
- Trial name
- NCT06752850
- Testing
- Efanesoctocog alfa
- Where
- 10 sites in Italy, Norway and 2 more
- Volunteers
- 37 people
- Sponsor
- Swedish Orphan Biovitrum
Hemophilia, Hemophilia A
Viscoelastic Properties of Lower Extremity Muscles in Patients With Hemophilia
The aim of our study is to evaluate the viscoelastic properties of lower extremity muscles in patients with hemophilia A and hemophilia B secondarily to compare them with their healthy peers.
- Conditions
- Hemophilia, Hemophilia A, Hemophilia B
- Trial name
- NCT05981313
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hasan Kalyoncu University
Hemophilia A, Severe, Hemophilia Arthropathy
Effect of Exercise in Pediatric Hemophilia
This study investigates the effect of exercise training on pain, physical activity and quality of life in pediatric hemophilia patients.
- Trial name
- NCT04754997
- Testing
- Traditional exercise training, Specific exercise training
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Hasan Kalyoncu University
Hemophilia A
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult patients with hemophilia A.
- Trial name
- RH-107-III02 (NCT04845399)
- Testing
- Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- Where
- 16 sites in China
- Volunteers
- 101 people
- Sponsor
- Zhengzhou Gensciences Inc
Hemophilia A
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.
- Trial name
- NCT00168051
- Testing
- ReFacto, Advante
- Where
- 13 sites in United States, Belgium and 6 more
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Blood Disease, Hemophilia A
Hepatitis C in Clinically Discordant Hemophilic Siblings
To define the natural history, immunologic, and genetic factors that influence the clinical outcome of hepatitis C in a cohort of hemophilic siblings.
- Conditions
- Blood Disease, Hemophilia A, Hepatitis, Viral, Human
- Trial name
- NCT00007371
- Sponsor
- University of North Carolina, Chapel Hill
Hemophilia
Examination of Physiotherapists' Knowledge, Awareness and Competence on Physical Activity and Exercise in Hemophilia Patients
This study aims to assess physiotherapists' knowledge levels, awareness, perceived roles, adequacy of education received, learning preferences, and external barriers regarding exercise and physical activity in individuals with…
- Trial name
- NCT06879392
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Hemophilia A, Hemophilia B
Gait Evaluation in Haemophiliac Patients
Joint damage secondary to recurrent haemarthroses and chronic synovitis represents the commonest clinical manifestation of haemophilia.
- Trial name
- GAIT_GENERAL (NCT00824798)
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- ONE (NCT00703911)
- Testing
- eptacog alfa (activated)
- Where
- 16 sites in Algeria, Austria and 14 more
- Volunteers
- 102 people
- Sponsor
- Novo Nordisk A/S
Hemophilia A
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
The purpose of this study is to determine the pharmacokinetics and safety of Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) reconstituted in 2 mL sterile water for injection (SWFI) and compare with those…
- Trial name
- NCT00952822
- Testing
- Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
Comparison of Ideal vs. Actual Weight Base Factor Dosing
This is a randomized, prospective, multicenter study to examine whether or not the current recommended factor dosing strategy - i.e., dosing by actual body weight - in overweight and obese patients with Hemophilia A may deliver…
- Trial name
- NCT03286153
- Testing
- Ideal Body Weight First, Actual Body Weight First
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bloodworks
Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use.
- Trial name
- explorer8 (NCT04082429)
- Testing
- Concizumab
- Where
- 113 sites in United States, Algeria and 31 more
- Volunteers
- 156 people
- Sponsor
- Novo Nordisk A/S
Hemophilia
Gait Examination in Patients With Hemophilia in Austria
Hemophilia is an inherited disease caused by deficiency in varying degrees of clotting factors VIII and IX. Depending on the percentage of clotting factor in the blood the disease is categorized as "severe" (<1%, characterized by…
- Trial name
- JOSEPHA (NCT03541811)
- Testing
- 3-d gait examination (level walking), Anthropometrics and body composition assessment, Biomarkers
- Where
- Austria
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hochschule Campus Wien (University of Applied Sciences Campus Vienna)